StockData
Skinvisible, Inc. logo

Skinvisible, Inc. (SKVI) stock

SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
$0.16+0.00 (+0.06%)

Close on Oct 19, 2026Market cap $843.54KP/E –Yield –

Skinvisible operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Skinvisible's operating income for the twelve months ending Jun 30, 2026 was -$458.98K. For fiscal 2025 it was -$496.32K. The highest annual figure on record is $188.08K in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$496.32K–
FY2024Dec 31, 2024-$589.59K–
FY2023Dec 31, 2023-$490.38K–
FY2022Dec 31, 2022-$238.43K-226.8%
FY2021Dec 31, 2021$188.08K–
FY2020Dec 31, 2020-$253.67K–
FY2019Dec 31, 2019-$539.78K–
FY2018Dec 31, 2018-$597.94K–
FY2017Dec 31, 2017-$364.16K–
FY2016Dec 31, 2016-$841.70K–
FY2015Dec 31, 2015-$1.08M–
FY2014Dec 31, 2014-$1.17M–
FY2013Dec 31, 2013-$759.53K–
FY2012Dec 31, 2012-$1.32M–
FY2011Dec 31, 2011-$1.23M–
FY2010Dec 31, 2010-$800.24K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$112.82K–
Q1 FY2026Mar 31, 2026-$125.94K–
Q4 FY2025Dec 31, 2025-$114.17K–
Q3 FY2025Sep 30, 2025-$106.06K–
Q2 FY2025Jun 30, 2025-$136.24K–
Q1 FY2025Mar 31, 2025-$139.85K–
Q4 FY2024Dec 31, 2024-$198.74K–
Q3 FY2024Sep 30, 2024-$124.97K–
Q2 FY2024Jun 30, 2024-$142.69K–
Q1 FY2024Mar 31, 2024-$123.18K–
Q4 FY2023Dec 31, 2023-$136.54K–
Q3 FY2023Sep 30, 2023-$113.11K–
Q2 FY2023Jun 30, 2023-$112.82K-176.5%
Q1 FY2023Mar 31, 2023-$127.90K–
Q4 FY2022Dec 31, 2022-$117.72K-173.8%
Q3 FY2022Sep 30, 2022-$127.17K–
Q4 FY2021Dec 31, 2021$147.54K+1813.4%
Q3 FY2021Sep 30, 2021-$7.85K–
Q2 FY2021Jun 30, 2021$159.52K–
Q1 FY2021Mar 31, 2021-$111.13K–
Q4 FY2020Dec 31, 2020$7.71K–
Q3 FY2020Sep 30, 2020-$118.62K–
Q2 FY2020Jun 30, 2020-$12.76K–
Q1 FY2020Mar 31, 2020-$129.99K–
Q4 FY2019Dec 31, 2019-$117.46K–
Q3 FY2019Sep 30, 2019-$136.93K–
Q2 FY2019Jun 30, 2019-$139.30K–
Q1 FY2019Mar 31, 2019-$146.09K–
Q4 FY2018Dec 31, 2018-$153.42K-162.5%
Q3 FY2018Sep 30, 2018-$138.64K–
Q2 FY2018Jun 30, 2018-$131.31K–
Q1 FY2018Mar 31, 2018-$174.57K–
Q4 FY2017Dec 31, 2017$245.39K–
Q3 FY2017Sep 30, 2017-$141.62K–
Q2 FY2017Jun 30, 2017-$313.71K–
Q1 FY2017Mar 31, 2017-$154.23K–
Q4 FY2016Dec 31, 2016-$153.12K–
Q3 FY2016Sep 30, 2016-$201.73K–
Q2 FY2016Jun 30, 2016-$172.78K–

More Skinvisible figures

See a number that looks wrong?